Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Follow-Up Questions
Lineage Cell Therapeutics Inc 'in CEO'su kimdir?
Mr. Brian Culley 2018 'den beri şirketle birlikte olan Lineage Cell Therapeutics Inc 'in Chief Executive Officer 'ıdır.
LCTX hissesinin fiyat performansı nasıl?
LCTX 'in mevcut fiyatı $1.48 'dir, son işlem günde 4.43% decreased etti.
Lineage Cell Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Lineage Cell Therapeutics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 8 analist Lineage Cell Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 8 al, 2 tut, 0 sat ve 3 güçlü sat içermektedir
